Compare · A vs WAT
A vs WAT
Side-by-side comparison of Agilent Technologies Inc. (A) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $48.78B, about 1.1x WAT ($45.43B).
- WAT has been more active in the news (9 items in the past 4 weeks vs 7 for A).
- Both have 25 recent analyst ratings on file.
- Company
- Agilent Technologies Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $48.78B
- $45.43B
- 1M return
- -0.72%
- -
- 1Y return
- +18.63%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1999
- 1995
- News (4w)
- 7
- 9
- Recent ratings
- 25
- 25
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest A
- Agilent to Participate in 9th Annual Evercore Healthcare Conference
- Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme
- Agilent Completes Acquisition of Proscia
- Agilent Launches 5987A MSD with GC Assist for Faster, Smarter GC/MS Workflows
- Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
- Agilent and University of Chicago Launch Center of Excellence for Energy Materials Research
- Deutsche Bank initiated coverage on Agilent with a new price target
- Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
- Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
- Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
Latest WAT
- SEC Form 10-Q filed by Waters Corporation
- Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
- New insider Conly D Steven claimed ownership of 6,030 shares (SEC Form 3)
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
- Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery
- Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
- Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
- Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
- Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release